Aliases:This biomarker is also known as:
- monocyte secretory protein JE,
- small inducible cytokine subfamily A (Cys-Cys), member 2,
- Small-inducible cytokine A2,
- Monocyte chemotactic and activating factor,
- Monocyte chemotactic protein 1,
- C-C motif chemokine 2,
- chemokine (C-C motif) ligand 2,
- Monocyte chemoattractant protein 1,
- small-inducible cytokine A2,
- monocyte chemoattractant protein 1,
- monocyte chemotactic and activating factor,
- monocyte chemotactic protein 1,
- small inducible cytokine A2 (monocyte chemotactic protein 1, homologous to mouse Sig-je),
- monocyte chemoattractant protein-1,
- Monocyte secretory protein JE,
From NCBI Gene: This gene is one of several cytokine genes clustered on the q-arm of chromosome 17. Chemokines are a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. The superfamily is divided into four subfamilies based on the arrangement of N-terminal cysteine residues of the mature peptide. This chemokine is a member of the CC subfamily which is characterized by two adjacent cysteine residues. This cytokine displays chemotactic activity for monocytes and basophils but not for neutrophils or eosinophils. It has been implicated in the pathogenesis of diseases characterized by monocytic infiltrates, like psoriasis, rheumatoid arthritis and atherosclerosis. It binds to chemokine receptors CCR2 and CCR4. [provided by RefSeq, Jul 2013]
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
|QA State:||Under Review|
No additional breast data available.
CCL2, also known as MCP-1, was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
|UniProt Accession #:||P13500|
|Mutated Sites Count:||24|
|Associated Pubmed ID Count||4|
|Affected Protein Function Sites Count:||4|